The BC Cancer Foundation is thrilled to announce that its 2010 Inspiration Gala Sunday night raised a record $2.69 million to fund a new and first-of-its-kind lymphoma research project in B.C. at the BC Cancer Agency. Lymphoma is one of the fastest-growing, and now the fourth most common cancers in B.C. and North America. The Angelyc Project will be the first-of-its-kind study of the entire DNA of all lymphomas, both Hodgkin and non-Hodgkin types.
The research is expected to change the landscape for lymphoma research in B.C. and the lives of lymphoma patients and their families across Canada and potentially around the world.
Visit www.bccancerfoundation.com to make a donation or to learn how you can make a difference in the lives of those affected by cancer.
Two-time lymphoma survivor Kathy McLaughlin told guests she was a living miracle. "I wouldn't be here to tell my story if it weren't for the advances in treatment made possible by research," she said. "That is why I believe so strongly in the ANGELYC Project - we have the chance, right here in B.C., to invest in breakthrough research that could mean the difference between life and death for thousands of people diagnosed with lymphoid cancers in the future."
BC Cancer Foundation President and CEO Douglas Nelson thanked Gala sponsors, donors and guests for their generosity. "Your partnership in this
The Foundation's Inspiration Galas have now raised close to $8 million for cancer research at the BC Cancer Agency and directly funded four recent breakthroughs in ovarian cancer.
The BC Cancer Foundation is the bridge that connects philanthropic support and research breakthroughs in cancer knowledge. As the fundraising partner of the BC Cancer Agency and the largest charitable funder of cancer research in this province, we enable donors to make contributions to leading-edge research that have a direct impact on improvements to cancer care for patients in British Columbia. As an independent charitable organization, we raise funds exclusively for the BC Cancer Agency to support innovative cancer research and compassionate enhancements to patient care.
-30-
Media contact: Judy Hamill, Tel: 604-707-5934; Cell: 604-802-6984; [email protected]
